Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
BUSINESS
JCR Chief Delays Global Licensing Timeline for Lysosomal Storage Disorder Therapies
JCR Pharmaceuticals aims to strike a global licensing deal for its lysosomal storage disease treatments by the end of this fiscal year through March 2021 after picking a partner in the first half, Chairman and President Shin Ashida said on…
To read the full story
Related Article
- JCR Can Strike Global Licensing Deal for Lysosomal Therapies at Least by March-End: Chief
November 4, 2020
- JCR Aims to File Sakigake-Designated Hunter Syndrome Drug in September
May 19, 2020
- JCR Closes ArmaGen Buyout, Gaining IP Rights on Blood-Brain Barrier-Penetrating Technology
April 21, 2020
- JCR Acquiring ArmaGen to Expedite Drug Development for Lysosomal Diseases
March 27, 2020
- JCR to License Lysosome Storage Disease Treatment to Global Player by March 2020: Chairman
May 20, 2019
BUSINESS
- Fuji Curbs Shipments of Simponi, Ranmark Biosimilars Soon after Launch
September 4, 2026
- Leqembi Subcutaneous Autoinjector Approved in China
September 4, 2026
- Nxera Gets US$8.6 Million OX2R Milestone from Centessa
September 4, 2026
- Top Medipal Shareholder Seeks CEO Ouster, Special Dividend
September 4, 2026
- Nipro Grabs Japan Approval for Stelara IV Biosimilar
September 4, 2026
Japan has entered a third straight year of wage hikes averaging 5%, but the pharmaceutical industry is struggling to keep…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…